Initial Beneficial Ownership · 3
Erasca, Inc.
ERASNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
ownership.xml
Filing details
- Report period
- 2026-08-10
- Issuer
- Erasca, Inc.
- Issuer CIK
- 0001761918
- Trading symbol
- ERAS
- No securities owned
- Checked
Reporting owner 1
- Name
- Fuchs Charles S.
- Reporting owner CIK
- 0001719576
- Relationship
- Officer
- Officer title
- President, R&D
- Address
- C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO, CA, 92121
Signature 1
- Signed
- /s/ Ebun S. Garner, as Attorney-in-Fact
- Date
- 2026-08-12
Company context
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.